DENVER , Oct. 29, 2024 /PRNewswire/ -- DaVita Inc. (NYSE: DVA ) announced financial and operating results for the quarter ended September 30, 2024.
"We continue to provide quality care for our patients across the continuum of care, while delivering solid third quarter financial performance," said Javier Rodriguez , CEO of DaVita Inc. "And, in light of recent severe storms, I am grateful for the remarkable resilience of our patients and our frontline caregivers." Financial and operating highlights for the quarter ended September 30, 2024: Consolidated revenues were $3.
264 billion . Operating income was $535 million . Diluted earnings per share was $2.
50 and adjusted diluted earnings per share was $2.59 . Operating cash flow was $810 million and free cash flow was $555 million .
Incurred an incremental Term Loan A-1 tranche in the aggregate principal amount of $1.1 billion and issued an aggregate principal amount of $1.0 billion of 6.
875% senior notes. A portion of the proceeds of these transactions was used to repay the Term Loan B-1 maturing in 2026 of approximately $950 million and the balance then outstanding on our revolving line of credit. Repurchased 2.
7 million shares of our common stock at an average price paid of $147.20 per share. U.
S. dialysis metrics: Volume: Total U.S.
dialysis treatments for the third quarter of 2024 were 7,350,784, or an average of 93,048 treatments per day, representing a per day decrease of (0.1)% compared to the second quarter of 2024. Normal.
